| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | 0.19 | 5e-09 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | 0.19 | 1e-07 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 3e-06 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | 0.21 | 1e-05 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | -0.2 | 0.0001 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0001 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | 0.21 | 0.0002 |
| mRNA | KU-0063794 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0003 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0005 |